Stock listing

NASDAQ:KROS Keros Therapeutics, Inc. Stock

Home listing (NASDAQ) of Keros Therapeutics, Inc.

Follow Keros Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KROS

$11.08 USD -0.92 (-7.7%)

Close on Nov 20, 2026

Past year -34.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$11.04 – $11.59 USDNov 20, 2026
Volume
208,691 sharesNov 20, 2026
Market cap
$219.7M USDAt the close on Nov 20, 2026 · price × 19.83M shares outstanding
52-week range
$8.98 – $22.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.13M USDMedian day 180,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Keros Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KROS · Home$11.08 USD-0.92 (-7.7%)208,691$11.13$11.59$11.04$12.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KROS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$11.08-0.92-7.7%$11.13$11.59$11.04208,691
$12.00+0.69+6.1%$11.23$12.40$11.23547,064
$11.31+1.28+12.8%$10.02$11.76$10.02423,103
$10.03-0.27-2.6%$10.33$10.74$9.905193,875
$10.30+0.22+2.2%$10.06$10.55$9.55167,040
$10.08+0.54+5.7%$9.51$10.53$9.435630,066
$9.54+0.21+2.3%$9.37$9.725$9.23221,662
$9.33+0.16+1.7%$9.20$9.50$8.98274,357
$9.17-0.19-2.0%$9.50$9.87$9.10144,125
$9.36-0.09-1.0%$9.74$9.955$9.26192,037
$9.45-1.38-12.7%$10.84$10.98$9.37238,369
$10.830.000.0%$11.13$11.15$10.80128,258
$10.83+0.07+0.7%$10.78$11.11$10.78105,963
$10.76-0.28-2.5%$11.12$11.39$10.53139,244
$11.04-0.32-2.8%$11.36$11.49$10.98120,157
$11.36-0.25-2.2%$11.71$11.87$11.21205,017
$11.61+0.185+1.6%$11.34$11.79$11.20183,223
$11.43+0.095+0.8%$11.37$11.60$11.19148,511
$11.33+0.05+0.4%$11.30$11.51$11.20112,409
$11.28-0.07-0.6%$11.28$11.34$10.92120,900
$11.35+0.17+1.5%$11.15$11.44$11.15115,500
$11.18-0.22-1.9%$11.40$11.68$11.11178,100
$11.40+0.34+3.1%$11.04$11.67$11.04153,400
$11.06+0.40+3.8%$10.68$11.15$10.66210,600
$10.66-0.44-4.0%$11.11$11.13$10.63169,600
$11.10+0.05+0.5%$11.13$11.40$10.9896,700
$11.05-0.18-1.6%$11.07$11.30$10.92159,100
$11.23-0.38-3.3%$11.65$11.69$11.19144,300
$11.61-0.34-2.8%$11.77$12.08$11.58223,700
$11.95+0.31+2.7%$11.58$12.26$11.49194,400
$11.64+0.43+3.8%$11.13$11.76$10.99245,700
$11.21+0.20+1.8%$10.81$11.34$10.81196,000
$11.01-0.51-4.4%$11.56$11.63$10.95185,300
$11.52+0.16+1.4%$11.38$11.56$11.07132,400
$11.36+0.10+0.9%$11.38$11.44$11.01231,500
$11.26-0.14-1.2%$11.38$11.44$11.08140,200
$11.40+0.21+1.9%$11.25$11.58$11.16131,200
$11.19-0.09-0.8%$11.24$11.46$11.15118,300
$11.28-0.34-2.9%$11.33$11.41$10.93208,600
$11.62+0.07+0.6%$11.54$11.70$11.29216,100
$11.55-0.08-0.7%$11.60$11.60$10.97284,400
$11.63-0.10-0.9%$11.68$11.82$11.47157,500
$11.73+0.25+2.2%$11.54$12.05$11.43189,800
$11.48+0.29+2.6%$11.31$11.60$11.08120,700
$11.19-0.17-1.5%$11.32$11.40$11.10302,500
$11.36+0.62+5.8%$10.87$11.39$10.83274,100
$10.74-0.43-3.8%$11.23$11.23$10.70273,600
$11.17-0.04-0.4%$11.16$11.21$10.72200,000
$11.21+0.13+1.2%$11.10$11.34$10.98342,200
$11.08-0.09-0.8%$11.25$11.34$11.03143,800
$11.17-0.14-1.2%$11.16$11.20$11.00128,800
$11.31+0.14+1.3%$11.48$11.82$11.21188,500
$11.17-0.15-1.3%$11.16$11.31$10.9873,000
$11.32+0.21+1.9%$11.03$11.40$11.0265,600
$11.11-0.12-1.1%$11.27$11.32$10.92148,700
$11.23+0.16+1.4%$11.07$11.49$10.9798,000
$11.07-0.01-0.1%$11.02$11.13$10.8396,200
$11.08+0.05+0.5%$10.93$11.20$10.76180,000
$11.03-0.20-1.8%$11.15$11.16$10.58328,300
$11.23+0.11+1.0%$11.09$11.48$11.01127,600
$11.12-0.56-4.8%$11.66$11.66$11.08113,600
$11.68+0.90+8.3%$10.83$11.71$10.83200,300
$10.78-0.25-2.3%$11.12$11.12$10.72217,100
$11.03+0.08+0.7%$10.96$11.09$10.81157,500
$10.95-0.15-1.4%$11.09$11.10$10.55203,100
Ticker
NASDAQ:KROS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Keros Therapeutics, Inc. news

Keros Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 141 in all · newest Nov 16, 2026 · oldest 2020
Decks
42 decks · latest Nov 5, 2026

Where Keros Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KROS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KROSBOATSUnited StatesUSD

Valuation

EV/sales −0.6× against a median of 99.4×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$24.67M USD
P/E
Loss
EV/sales
−0.6×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
Not reported
Operating margin
−181.3%
Net margin
−152.7%
Debt to equity
0.1×
Beta vs S&P 500
1.16

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Keros Therapeutics, Inc. · NASDAQ:KROSUS$219.7M−US$24.67Mn/a−0.6×n/a0.8×−152.7%0.1×1.16
Enanta Pharmaceuticals, Inc. · NASDAQ:ENTAUS$222.2MUS$82.43Mn/a1.3×n/a2.8×−108.3%0.7×1.11
Clover Biopharmaceuticals Ltd. · HKEX:2197US$222.0MUS$206.5Mn/a403×n/an/an/an/an/a
Aprilbio Co., Ltd. · KRX:397030US$221.1MUS$161.1Mn/an/an/a3.1×n/a0.0×n/a
Northwest Biotherapeutics, Inc. · OTC:NWBOUS$220.0MUS$283.8Mn/a99.4×n/an/an/an/a0.90
Immuneering Corporation · NASDAQ:IMRXUS$218.7MUS$160.5Mn/an/an/a1.3×n/a0.0×1.17
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Median of the othersUS$218.1MUS$160.7M99.4×1.6×−108.3%0.1×1.17

Forecasts

4 strong buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
20.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.46 · 4 analysts
Revenue, year to Dec 2026
40.82M · 6 analysts

Team and board

Officers

OfficerRole
Jasbir SeehraPresident, Chief Executive Officer and Director
Annita TaniniCorporate Controller and Vice President, Finance
Esther ChoChief Legal Officer
Lorena LernerChief Scientific Officer

Board

DirectorRole
Jean-Jacques BienaiméChairman
Alpna SethDirector
Anne PrenerDirector
Charles NewtonDirector
Jasbir SeehraPresident, Chief Executive Officer and Director
Julius KnowlesDirector
Mary Ann GrayDirector
Nima FarzanDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−0.9%
Q2 2026Aug 3, 2026 · After close+1.4%
Q1 2026Apr 30, 2026+3.5%
Q4 2025Mar 4, 2026 · After close−15.0%
Q3 2025Nov 5, 2025 · After close+3.3%
Q2 2025Aug 6, 2025 · After close−7.3%
Q1 2025May 6, 2025 · After close−0.4%
Q4 2024Feb 26, 2025 · Before open+0.3%
Q3 2024Nov 6, 2024 · After close+1.1%
Q2 2024Aug 7, 2024 · After close−2.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open−0.8%
Q4 2023Feb 28, 2024 · After close−0.8%
Q3 2023Nov 6, 2023 · Before open−0.8%
Q2 2023Aug 7, 2023 · Before open−1.7%
Q1 2023May 4, 2023 · After close−3.1%
Q4 2022Mar 3, 2023 · After close−12.0%
Q3 2022Nov 3, 2022 · Before open+1.7%
Q2 2022Aug 4, 2022 · After close+12.8%
Q1 2022May 5, 2022 · Before open−7.2%
Q4 2021Mar 9, 2022 · After close+0.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck24 slidesNov 5, 2026
Investor Presentation (August 2026)Investor deck24 slidesAugust 2026
Investor Presentation (March 2026)Investor deck24 slidesMar 4, 2026
Investor Presentation (January 2026)Investor deck23 slidesJan 9, 2026
Investor Presentation (August 2025)Investor deck34 slidesAug 6, 2025
Technical Presentation (May 2025)Technical14 slidesMay 29, 2025
Proxy Contest (May 2025)Proxy contest36 slidesMay 21, 2025
Proxy Contest (May 2025)Proxy contest27 slidesMay 19, 2025
Corporate Update (March 2025)Corporate update30 slidesMar 31, 2025
Investor Presentation (January 2025)Investor deck38 slidesJan 10, 2025
All 42 decks
DeckKindSlidesDate
Investor Presentation (August 2024)Investor deck38 slidesAug 7, 2024
Corporate Update (June 2024)Corporate update34 slidesJun 17, 2024
Investor Presentation (March 2024)Investor deck50 slidesMar 6, 2024
Investor Presentation (January 2024)Investor deck49 slidesJan 3, 2024
65th Annual Congress of the American Society of Hematology 2023Conference33 slidesDec 11, 2023
Investor Presentation (November 2023)Investor deck33 slidesNov 6, 2023
Investor Presentation (August 2023)Investor deck33 slidesAug 7, 2023
Technical Presentation (August 2023)Technical29 slidesAug 7, 2023
28th Annual Congress of the European Hematology Association (June 2023)Conference22 slidesJun 9, 2023
Investor Presentation (January 2023)Investor deck32 slidesJan 9, 2023
64th Annual Congress of the American Society of Hematology 2022Conference27 slidesDec 12, 2022
Investor Presentation (August 2022)Investor deck47 slidesAug 4, 2022
Investor Presentation (June 2022)Investor deck22 slidesJun 10, 2022
Corporate Update (May 2022)Corporate update25 slidesMay 18, 2022
Investor Presentation (March 2022)Investor deck36 slidesMar 9, 2022
ASBMR 2022Conference16 slides2022
Corporate Update (December 2021)Corporate update26 slidesDec 13, 2021
Technical Presentation (November 2021)Technical14 slidesNov 14, 2021
Investor Presentation (November 2021)Investor deck28 slidesNov 4, 2021
Investor Presentation (June 2021)Investor deck32 slidesJun 22, 2021
Corporate Update (June 2021)Corporate update20 slidesJun 22, 2021
Investor Presentation (May 2021)Investor deck27 slidesMay 6, 2021
Investor Presentation (March 2021)Investor deck27 slidesMar 25, 2021
Technical Presentation (March 2021)Technical13 slidesMarch 2021
Technical Presentation (December 2020)Technical5 slidesDec 7, 2020
American Society of Hematology Annual Meeting 2020Conference11 slidesDecember 2020
Technical Presentation (December 2020)Technical10 slidesDecember 2020
Technical Presentation (December 2020)Technical11 slidesDecember 2020
Investor Presentation (November 2020)Investor deck27 slidesNov 10, 2020
Investor Presentation (September 2020)Investor deck28 slidesSep 8, 2020
Investor Presentation (June 2020)Investor deck27 slidesJun 2, 2020
Technical Presentation (June 2020)Technical12 slidesJune 2020

Open Decks

IPO

Priced at US$16.00 a share on Apr 7, 2020.

Price
US$16.00 a share
Shares offered
6,000,000 shares of common stock
Offering size
US$96 million
Underwriters' option
Up to 900,000 more shares
Underwriters
Jefferies, SVB Leerink, Piper Sandler, H.C. Wainwright & Co. · In the order on the cover
Shares delivered
On or about Apr 13, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJan 21, 2020
Filed publiclyMar 16, 2020
Amended twiceNewest Apr 7, 2020
Shares registered with an exchangeApr 3, 2020
Declared effective by the SECApr 7, 2020
Final prospectus, with the priceApr 8, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Apr 8, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue243.9M0151.0K020.1M010.0M10.0M
Cost of revenue1.51M1.23M815.0K1.61M898.0K605.0K17.3M10.1M
Gross profit242.6M3.55M151.0K-1.61M20.1M-605.0K-7.35M-111.0K
Research and development129.6M173.6M135.3M87.3M55.1M33.9M17.4M10.1M
Selling, general and administrative46.8M40.8M34.8M27.5M21.3M12.8M3.18M1.58M
Operating income67.6M-210.8M-169.9M-114.8M-56.4M-46.7M-10.6M-1.69M
Depreciation and amortization1.51M1.23M815.0K674.0K378.0K278.0K208.0K153.0K
EBITDA69.1M-209.6M-169.1M-114.1M-56.0M-46.4M-10.4M-1.54M
Interest expense001.00K4.00K6.00K8.00K6.00K
Income before tax91.9M-187.1M-153.0M-104.7M-56.7M-45.5M-12.3M-1.08M
Income tax4.88M300.0K002.01M-172.0K0257.0K
Net income87.0M-187.4M-153.0M-104.7M-58.7M-45.4M-12.3M-1.33M
Earnings per share, basic2.34-5.00-5.20-4.15-2.52-2.93-6.08-0.15
Earnings per share, diluted2.30-5.00-5.20-4.15-2.52-2.93-6.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents287.4M559.9M331.1M279.0M230.0M265.9M7.02M23.3M
Receivables3.57M2.74M143.0K018.0M0922.0K
Inventory14.1M-841.0K3.06M1.47M759.0K
Current assets315.4M588.9M347.3M285.8M251.4M267.7M8.93M25.5M
Property, plant and equipment4.30M4.24M4.13M2.02M1.33M724.0K708.0K1.38M
Total assets338.0M615.9M370.0M306.8M255.3M269.4M11.0M27.4M
Accounts payable1.97M4.60M5.45M3.34M3.65M2.15M2.09M501.0K
Current liabilities20.4M27.4M24.4M16.5M11.8M7.18M4.49M11.5M
Long-term debt4.96M2.39M
Total debt16.9M18.9M14.4M13.3M1.09M899.0K5.33M2.56M
Total liabilities34.9M44.3M37.8M29.4M12.1M7.72M10.5M14.7M
Shareholders' equity303.1M571.6M332.2M277.4M243.2M261.7M-19.4M12.8M
Shares outstanding19.5M40.6M31.8M27.5M24.0M23.2M2.43M8.88M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations107.5M-160.9M-124.5M-70.1M-62.1M-36.9M-16.0M7.04M
Capital spending-1.55M-1.93M-2.46M-1.24M-1.02M-294.0K-271.0K-217.0K
Free cash flow106.0M-162.8M-127.0M-71.3M-63.2M-37.2M-16.3M6.83M
Cash from investing-1.55M-1.93M-2.46M-1.24M-1.02M-294.0K-271.0K-217.0K
Cash from financing-378.5M391.8M179.0M120.3M28.6M296.0M14.0K11.5M
Share buybacks-375.0M0120.3M28.6M299.0M14.0K11.5M
Change in cash-272.5M229.0M52.0M49.0M-34.6M258.9M-16.3M18.3M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
8-K · Current reportNov 16, 2026Current reportSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
8-K · Current reportNov 5, 2026Current reportSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
8-K · Current reportSep 29, 2026Current reportSEC
8-K · Current reportSep 28, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 17, 2026Other filingsSEC
DEL AMSep 11, 2026Other filingsSEC
S-3 · Registration statementSep 10, 2026Offer documentSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
3 · Initial statement of ownershipAug 13, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Current reportSEC
10-Q · Quarterly reportAug 3, 2026Quarterly reportSEC
8-K · Current reportAug 3, 2026ResultsSEC
8-K · Current reportJul 30, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
8-K · Current reportJul 22, 2026Management or board changeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2026Big-stake noticeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 6, 2026Insider tradeSEC
8-K · Current reportJun 25, 2026Management or board changeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
8-K · Current reportJun 3, 2026Meeting outcomeSEC
8-K · Current reportJun 1, 2026Current reportSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
4/A · Change in ownership, amendedMar 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
8-K · Current reportMar 9, 2026Current reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 4, 2026Offer documentSEC
10-K · Annual reportMar 4, 2026Annual reportSEC
8-K · Current reportMar 4, 2026ResultsSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
8-K · Current reportFeb 26, 2026Management or board changeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
8-K · Current reportFeb 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
8-K · Current reportJan 9, 2026Current reportSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
SC TO-I/ANov 20, 2025Acquisition or disposalSEC
SC TO-I/ANov 19, 2025Acquisition or disposalSEC
SCHEDULE 13G · Big-stake noticeNov 18, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 22, 2025Big-stake noticeSEC
SC TO-IOct 20, 2025Acquisition or disposalSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 16, 2025Big-stake noticeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 15, 2025Big-stake noticeSEC
SC TO-COct 15, 2025Other filingsSEC
8-K · Current reportOct 15, 2025ResultsSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
8-K · Current reportSep 8, 2025Current reportSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
8-K · Current reportAug 28, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 21, 2025Big-stake noticeSEC
8-K · Current reportAug 20, 2025Current reportSEC
3 · Initial statement of ownershipAug 15, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2025Insider tradeSEC
8-K · Current reportAug 6, 2025Management or board changeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
8-K · Current reportJul 17, 2025Current reportSEC
8-K · Current reportJul 15, 2025Management or board changeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 11, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 11, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Current reportSEC
8-K · Current reportMay 29, 2025Current reportSEC
DEFA14A · Additional proxy materialMay 27, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
8-K · Current reportMay 12, 2025Current reportSEC
DEFA14A · Additional proxy materialMay 8, 2025Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 8, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 2, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 28, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 18, 2025Big-stake noticeSEC
8-K · Current reportApr 18, 2025Material contractSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 11, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeApr 11, 2025Big-stake noticeSEC
8-A12B · Registration of shares for listing on an exchangeApr 10, 2025Other filingsSEC
8-K · Current reportApr 10, 2025Material contractSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
8-K · Current reportMar 31, 2025Current reportSEC
8-K · Current reportMar 6, 2025Current reportSEC
8-K · Current reportFeb 28, 2025Current reportSEC
S-8 · Registration statement for employee plansFeb 26, 2025Offer documentSEC
10-K · Annual reportFeb 26, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025ResultsSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
8-K · Current reportJan 30, 2025Current reportSEC
4/A · Change in ownership, amendedJan 24, 2025Insider tradeSEC
8-K · Current reportJan 21, 2025Current reportSEC
8-K · Current reportJan 15, 2025Current reportSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportDec 12, 2024Current reportSEC
8-K · Current reportDec 9, 2024Current reportSEC
8-K · Current reportDec 3, 2024Material contractSEC
8-K · Current reportNov 26, 2024Current reportSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 8, 2024Insider tradeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
8-K · Current reportNov 6, 2024Current reportSEC
8-K · Current reportOct 16, 2024Management or board changeSEC
8-K · Current reportSep 30, 2024Current reportSEC
8-K · Current reportSep 3, 2024Current reportSEC
8-K · Current reportAug 28, 2024Current reportSEC
4 · Change in ownershipAug 15, 2024Insider tradeSEC
4 · Change in ownershipAug 15, 2024Insider tradeSEC
144 · Notice of proposed saleAug 13, 2024Other filingsSEC
144 · Notice of proposed saleAug 13, 2024Other filingsSEC
8-K · Current reportAug 7, 2024Current reportSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
8-K · Current reportJun 17, 2024Current reportSEC
424B5 · ProspectusJun 17, 2024Offer documentSEC
8-K · Current reportJun 17, 2024Management or board changeSEC
8-K · Current reportJun 17, 2024Current reportSEC

This page holds 200 of 543 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Keros Therapeutics, Inc.’s releases

Common shares
19,827,188
Fully diluted
19,827,188

Fully diluted

LineShares
Common shares19,827,188

Share count over time

CountShares
Nov 22, 202619,827,188

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock3.5M17.8%US$39.9MSep 30, 2026
Vanguard1.61M8.2%US$18.4MSep 30, 2026
Nantahala Capital Management, LLC1.49M7.6%US$17MSep 30, 2026
AQR Capital Management LLC804K4.1%US$9.16MSep 30, 2026
Orbimed Advisors LLC759K3.9%US$8.65MSep 30, 2026
Mackenzie743K3.8%US$8.47MSep 30, 2026
Federated Hermes, Inc.707K3.6%US$8.06MSep 30, 2026
Madison Avenue Partners, LP627K3.2%US$7.14MSep 30, 2026
Two Sigma548K2.8%US$6.25MSep 30, 2026
State Street542K2.8%US$6.17MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital496K2.5%US$5.66MSep 30, 2026
Jacobs Levy Equity Management, Inc461K2.3%US$5.26MSep 30, 2026
Qube Research & Technologies Ltd435K2.2%US$4.96MSep 30, 2026
Dimensional404K2.1%US$4.6MSep 30, 2026
Renaissance Technologies346K1.8%US$3.95MSep 30, 2026
Bridgeway Capital Management, LLC271K1.4%US$3.08MSep 30, 2026
Goldman Sachs254K1.3%US$2.9MSep 30, 2026
Nuveen253K1.3%US$2.88MSep 30, 2026
ADAR1 Capital Management, LLC239K1.2%US$2.73MSep 30, 2026
Man Group plc231K1.2%US$2.63MSep 30, 2026
D. E. Shaw & Co., Inc.183K0.93%US$2.09MSep 30, 2026
Arrowstreet Capital, Limited Partnership173K0.88%US$1.97MSep 30, 2026
Schwab170K0.87%US$1.94MSep 30, 2026
Citadel163K0.83%US$1.85MSep 30, 2026
Northern Trust152K0.77%US$1.73MSep 30, 2026
Wells Fargo144K0.73%US$1.64MSep 30, 2026
Morgan Stanley135K0.69%US$1.54MSep 30, 2026
Empowered Funds, LLC131K0.67%US$1.49MSep 30, 2026
O'Shaughnessy Asset Management, LLC126K0.64%US$1.37MSep 30, 2026
HSBC126K0.64%US$1.43MSep 30, 2026
UBS124K0.63%US$1.41MSep 30, 2026
Marshall Wace, LLP116K0.59%US$1.32MSep 30, 2026
Jane Street101K0.51%US$1.15MSep 30, 2026
Acadian Asset Management LLC94,7650.48%US$1.08MSep 30, 2026
Quantinno Capital Management LP93,2420.48%US$1.06MSep 30, 2026
BNY88,2890.45%US$1.01MSep 30, 2026
BNP Paribas79,4980.41%US$906KSep 30, 2026
Millennium76,7600.39%US$875KSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.72,1390.37%US$822KSep 30, 2026
Invesco71,7820.37%US$818KSep 30, 2026
Los Angeles Capital Management LLC69,8840.36%US$797KSep 30, 2026
Point72 Asset Management, L.P.66,6800.34%US$760KSep 30, 2026
Bank of America63,7900.33%US$727KSep 30, 2026
Ameriprise63,7660.32%US$727KSep 30, 2026
RBF Capital, LLC62,8000.32%US$716KSep 30, 2026
Susquehanna62,1570.32%US$709KSep 30, 2026
Panagora Asset Management Inc60,8300.31%US$693KSep 30, 2026
T. Rowe Price58,0110.30%US$662KSep 30, 2026
Barclays55,4050.28%US$632KSep 30, 2026
Ieq Capital, LLC54,7670.28%US$624KSep 30, 2026

This page holds 50 of 130 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund595K3.0%US$6.37MJun 30, 2026
iShares Russell 2000 ETF504K2.6%US$5.39MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund382K1.9%US$3.85MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund259K1.3%US$2.77MJun 30, 2026
Vanguard Extended Market Index Fund221K1.1%US$2.36MJun 30, 2026
BlackRock Advantage Small Cap Core Fund220K1.1%US$2.48MMay 29, 2026
Fidelity Small Cap Index Fund200K1.0%US$2.02MJul 31, 2026
Nuveen Quant Small Cap Equity Fund190K0.97%US$1.91MJul 31, 2026
iShares Russell 2000 Value ETF175K0.89%US$1.87MJun 30, 2026
Vanguard Explorer Fund171K0.87%US$1.72MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund150K0.76%US$1.69MMay 31, 2026
Bridge Builder Small/Mid Cap Growth Fund149K0.76%US$1.6MJun 30, 2026
Old Westbury Small & Mid Cap Strategies Fund144K0.73%US$1.45MJul 31, 2026
U.S. Small Cap Value Portfolio142K0.72%US$1.43MJul 31, 2026
EA Bridgeway Omni Small-Cap Value ETF129K0.66%US$1.34MJun 30, 2026
iShares Biotechnology ETF129K0.65%US$1.37MJun 30, 2026
Federated Hermes MDT Small Cap Growth Fund116K0.59%US$1.17MJul 31, 2026
Fidelity Extended Market Index Fund104K0.53%US$1.17MMay 31, 2026
iShares U.S. Small-Cap Equity Factor ETF103K0.53%US$1.04MJul 31, 2026
Multi-Manager Small Cap Equity Strategies Fund98,7260.50%US$1.11MMay 31, 2026
Schwab U.S. Small-Cap ETF92,9450.47%US$1.05MMay 31, 2026
Dimensional US Small Cap Value ETF86,2470.44%US$869KJul 31, 2026
Avantis U.S. Small Cap Value ETF83,4740.43%US$939KMay 31, 2026
Ultra-Small Company Fund75,0000.38%US$803KJun 30, 2026
Principal U.S. Small-Cap ETF62,6610.32%US$670KJun 30, 2026
iShares Micro-Cap ETF61,9920.32%US$663KJun 30, 2026
NVIT Multi-Manager Small Company Fund58,5660.30%US$627KJun 30, 2026
U.S. Micro Cap Portfolio58,1030.30%US$585KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF55,9890.29%US$564KJul 31, 2026
Dimensional U.S. Small Cap ETF49,9880.25%US$503KJul 31, 2026
Vanguard Health Care Index Fund49,1200.25%US$553KMay 31, 2026
Schwab Small-Cap Index Fund45,2340.23%US$456KJul 31, 2026
BlackRock Advantage Small Cap Growth Fund44,9560.23%US$481KJun 30, 2026
Fidelity Total Market Index Fund44,8890.23%US$505KMay 31, 2026
SEI Select Small Cap ETF41,0450.21%US$439KJun 30, 2026
Omni Small-Cap Value Fund39,5000.20%US$423KJun 30, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF38,8190.20%US$437KMay 31, 2026
NVIT Small Cap Value Fund34,5410.18%US$370KJun 30, 2026
Master Small Cap Index Series34,0740.17%US$365KJun 30, 2026
Small Cap Equity Fund33,0890.17%US$354KJun 30, 2026
Small Company Growth Portfolio33,0600.17%US$354KJun 30, 2026
MFS Blended Research Small Cap Equity Fund31,6330.16%US$356KMay 31, 2026
WisdomTree U.S. SmallCap Fund30,1320.15%US$322KJun 30, 2026
Fidelity Series Total Market Index Fund30,1000.15%US$339KMay 31, 2026
Avantis U.S. Small Cap Equity ETF27,9740.14%US$315KMay 31, 2026
Nuveen Equity Index Fund26,2760.13%US$265KJul 31, 2026
Fidelity Small Cap Value Index Fund25,6980.13%US$275KJun 30, 2026
Nuveen Small Cap Blend Index Fund25,1470.13%US$253KJul 31, 2026
Ultra-Small Company Market Fund25,0000.13%US$268KJun 30, 2026
Select Biotechnology Portfolio24,5780.13%US$277KMay 31, 2026

This page holds 50 of 162 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Prener Anne
Director
Sale433USD 10.77US$4,663Nov 17, 2026
Prener Anne
Director
Sale142USD 11.03US$1,566Nov 17, 2026
Newton Charles W.
Director
Sale491USD 10.83US$5,318Nov 17, 2026
Newton Charles W.
Director
Sale60USD 11.05US$663Nov 17, 2026
Prener Anne
Director
Sale574USD 9.79US$5,619Nov 12, 2026
Newton Charles W.
Director
Sale551USD 10.30US$5,675Aug 18, 2026
Lerner Lorena Raquel
Officer: Chief Scientific Officer
Sale3,568USD 10.29US$36,715Aug 18, 2026
Cho Esther
Officer: Chief Legal Officer
Sale4,485USD 10.29US$46,151Aug 18, 2026
Tanini Annita
Officer: Corp. Controller & VP, Finance
Sale1,224USD 10.29US$12,595Aug 18, 2026
Bienaime Jean Jacques
Director
Buy1,000USD 10.27US$10,270Aug 17, 2026
All 18 trades
TradeTradeSharesPriceValueDate
Bienaime Jean Jacques
Director
Buy1,000USD 10.61US$10,610Jul 15, 2026
Bienaime Jean Jacques
Director
Buy1,000USD 10.19US$10,190Jun 15, 2026
Newton Charles W.
Director
Sale550USD 10.04US$5,522Jun 11, 2026
Farzan Nima
Director
Sale2,625USD 10.73US$28,166Jun 4, 2026
Knowles Julius
Director
Sale2,625USD 10.73US$28,166Jun 4, 2026
Seth Alpna
Director
Sale2,625USD 10.72US$28,140Jun 4, 2026
Bienaime Jean Jacques
Director
Buy1,000USD 10.58US$10,580May 15, 2026
Bienaime Jean Jacques
Director
Buy1,000USD 11.70US$11,700Apr 15, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock Portfolio Management LLC9.10%1.81MSep 30, 2026Schedule 13G
BlackRock, Inc.8.40%1.67MJun 30, 2026Schedule 13G
Nantahala Capital Management, LLC6.90%1.36MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Since at least Apr 7, 2020
Jean-Jacques Bienaimé
Other companies: Ascendis Pharma A/S (Director · Since at least Mar 23, 2026); Immunome, Inc. (Director · Since at least Nov 7, 2023); Incyte Corporation (Director · Since at least Jan 20, 2015); Immunic, Inc. (Director · Apr 16, 2014 – Sep 24, 2018 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 16, 2014 · Past); InterMune Inc (Director · Mar 26, 2012 – Sep 29, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Feb 7, 2012 · Past); BioMarin Pharmaceutical Inc. (Director · Jan 3, 2006 – May 20, 2024 · Past)
Director · Since at least Jun 1, 2024
Ran Nussbaum
Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Oct 21, 2022 · Past); ArQule Inc (Director · Nov 8, 2017 – Jan 16, 2020 · Past); VBI Vaccines Inc. (Director · Oct 30, 2017 – Oct 30, 2017 · Past); Kite Pharma Inc (Director · Jun 19, 2014 – Oct 3, 2017 · Past)
Director · Since at least Apr 7, 2020
Charles Newton
Other companies: Novavax, Inc. (Director · Since at least Apr 25, 2025); Coherus Oncology, Inc. (Director · Since at least May 4, 2022); Lyell Immunopharma, Inc. (Chief Financial Officer · Since at least Jun 16, 2021); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past)
Director · Since at least Feb 26, 2026
Mary Ann Gray
Other companies: BioAtla, Inc. (Director · Since at least Jun 16, 2022); Compass Therapeutics, Inc. (Director · Since at least Apr 26, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022); Palisade Bio, Inc. (Director · Jun 11, 2023 – Nov 21, 2023 · Past)
Director · Since at least Jun 1, 2022
Tomer Kariv
Other companies: 89bio Inc (Director · Nov 8, 2019 – Nov 11, 2019 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Dec 19, 2019 · Past); VBI Vaccines Inc. (Director · Jan 23, 2018 – Jan 31, 2019 · Past); Arno Therapeutics Inc (Director · Jan 12, 2016 – Sep 8, 2016 · Past)
Director · Since at least Apr 7, 2020
Anne Prener
Other companies: Damora Therapeutics, Inc. (Director · Since at least Jan 8, 2021); Kaleido Biosciences, Inc. (Director · Jun 30, 2021 – Jun 30, 2021 · Past); Rubius Therapeutics Inc (Director · May 12, 2021 – May 12, 2022 · Past)
Director · Since at least Jun 25, 2026
Alpna Seth
Other companies: Bio-Techne Corp (Director · Since at least Oct 26, 2017); Seagen Inc (Director · Mar 15, 2018 – Dec 14, 2023 · Past)
Director · Since at least May 1, 2023
Nima Farzan
Other companies: Latigo Biotherapeutics, Inc. (President and CEO, Director · Since at least Aug 6, 2026); Kinnate Biopharma Inc (CHIEF EXECUTIVE OFFICER, Director · Dec 2, 2020 – Apr 3, 2024 · Past)
Director · Since at least Apr 7, 2020
Yung H Chyung
Other companies: Tourmaline Bio Inc. (Chief Medical Officer · Oct 19, 2023 – Oct 19, 2023 · Past); Scholar Rock Holding Corporation (Chief Medical Officer · May 23, 2018 – Feb 14, 2022 · Past)
Chief Medical Officer · Nov 1, 2024 – Feb 18, 2025 · Past
All 21 people
PersonSeat
Alon Lazarus
Other companies: Werewolf Therapeutics, Inc. (Director · Since at least Dec 23, 2020)
Director · Apr 7, 2020 – Apr 13, 2020 · Past
Christopher Rovaldi
Other companies: Acceleron Pharma Inc (SVP, Program Mgmt and Ops · Apr 28, 2017 – Apr 3, 2018 · Past)
Chief Operating Officer · Feb 1, 2022 – Feb 18, 2025 · Past
Keith Regnante
Other companies: Wave Life Sciences Ltd. (Chief Financial Officer · Aug 16, 2016 – Mar 7, 2019 · Past)
CHIEF FINANCIAL OFFICER · Since at least Apr 7, 2020
Simon Peter Cooper
Other companies: Morphic Holding Inc (CMO · Mar 18, 2024 – Aug 16, 2024 · Past)
CHIEF MEDICAL OFFICER · Aug 2, 2021 – Feb 13, 2024 · Past
Annita TaniniCorporate Controller and Vice President, Finance · Since at least Aug 4, 2026
Claudia OrdonezChief Medical Officer · Apr 7, 2020 – Jun 11, 2021 · Past
Esther ChoChief Legal Officer · Since at least Aug 6, 2025
Jasbir SeehraPresident, Chief Executive Officer and Director · Since at least Apr 7, 2020
Jennifer LacheyChief Scientific Officer · Apr 7, 2020 – Jul 15, 2022 · Past
Julius KnowlesDirector · Since at least Apr 7, 2020
Lorena LernerChief Scientific Officer · Since at least Aug 6, 2025

Open People

Log in to ask 6ix AI your own questions about Keros Therapeutics, Inc.